Project Grant R43AI157185
- This $650,000 Project Grant awarded by the USDA National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) CFDA 10.310 program aims to evaluate the safety and efficacy of a genetically engineered Bacillus subtilis probiotic strain in reducing Salmonella colonization in broiler chickens. The primary awardee, the Regents of the University of Michigan, will develop a B. subtilis strain that secretes Salmonella-neutralizing nanobodies to directly...
- The University of Florida received a three-year, $635,000 Project Grant award from the United States Department of Agriculture National Institute of Food and Agriculture under the Agriculture and Food Research Initiative competitive grants program. The grant will fund research to develop significantly improved genetically engineered Salmonella vaccine vectors that synthesize and deliver multiple protective antigens from Eimeria maxima and E. tenella parasites. This aims to induce protective...
- This two-year, $999,824 project grant from the USDA National Institute of Food and Agriculture will support Intralytix Inc.'s efforts to optimize the application of its Salmonella-targeting phage product SalmoFresh in poultry processing facilities. The goals of the award made under the American Rescue Plan Centers of Excellence for Meat and Poultry Processing and Food Safety Research and Innovation Phase III program are to design a customized spray system for applying SalmoFresh, test its...
- This $256,000 Project Grant from the National Science Foundation's Division of Industrial Innovation, under the Engineering program (CFDA 47.041), funds the development of a rapid, simple, and low-cost Salmonella detection and quantification test. Secure Food Solutions, Incorporated will optimize a multi-layer 96-well microplate method to demonstrate 90% sensitivity and specificity for Salmonella in raw poultry and processing environment samples within 15 hours without pre-enrichment. They...
- This $175,000 Project Grant was awarded on September 1, 2025 by the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture (NIFA) under the Small Business Innovation Research (SBIR) Program (CFDA 10.212). The grant was awarded to Phycovax LLC, a small disadvantaged business in Carlsbad, California, to develop a feed-based vaccine utilizing engineered diatoms (microscopic algae) to produce Salmonella proteins that can protect poultry against multiple Salmonella...
- The University of Arkansas Division of Agriculture was awarded a $622,841 Project Grant from the United States Department of Agriculture National Institute of Food and Agriculture under the Agriculture and Food Research Initiative competitive grants program. The grant will fund research to develop a novel vaccination strategy to control Salmonella in chickens through three key objectives. The first objective aims to optimize and evaluate a DNA-based aptamer adjuvant targeting CD40 as a universal...
- The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...
- This NSF Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Invvax, Inc. provides $996,606.00 in funding from July 1, 2025 to June 30, 2027 to develop stable prophylactic antibodies (SPABs) as long-term preventative treatments for infectious diseases. The project aims to discover antibody mutations that significantly enhance stability, extending their lifespan from weeks to years. The initial focus is on influenza, with the goal of creating SPABs that could...
- This Project Grant was awarded by the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) federal grant program (CFDA 10.310). The University of Florida received $650,000.00 to further optimize and evaluate "Self-Destructing Attenuated Adjuvant Salmonella (SDAAS)" strains for in ovo (in the egg) administration to poultry embryos. The goal is to stimulate protective innate immunity and enhance the...
- This federal Project Grant award of $269,874 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of SOLAVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis (MTB) vaccine, by Solaris Vaccines, Inc. The goal is to create a scalable and cost-effective vaccine that triggers both systemic and pulmonary immunity to improve protection against tuberculosis (TB), which kills...
DEVELOPMENT OF PROPRIETARY BACTERIOPHAGE QBETA AS A VACCINE CARRIER PLATFORM FOR ANTI-SALMONELLA VACCINE - PROJECT SUMMARY VACCINES HAVE SAVED MILLIONS OF LIVES. HOWEVER, THERE ARE MANY DISEASES AGAINST WHICH VACCINES ARE NOT YET AVAILABLE, WITH THE CURRENT COVID-19 PANDEMIC IN THE WORLD SERVING AS A PAINFUL REMINDER OF THE NEED FOR VACCINES AGAINST EMERGING DISEASES. WITH THE GROWING EMPHASIS ON VACCINE SAFETY, NEXT-GENERATION VACCINE DESIGNS HAVE BEEN INCREASINGLY FOCUSING ON SUBUNIT ANTIGENS. BECAUSE SUBUNIT EPITOPES TEND TO HAVE LOWER IMMUNOGENICITY, IMMUNOGENIC CARRIERS ARE CRITICAL TO DELIVER THE DESIRED ANTIGEN TO THE IMMUNE SYSTEM AND TO ENHANCE THE IMMUNE RESPONSES. HOWEVER, THERE ARE VERY FEW CARRIERS AVAILABLE THAT HAVE BEEN VALIDATED IN CLINICAL STUDIES. IN THIS SBIR PHASE I PROJECT, IASO THERAPEUTICS, INC. WILL FOCUS ON THE DEVELOPMENT OF A PROPRIETARY BACTERIOPHAGE MUTANT QSS (MQSS) VIRUS LIKE PARTICLE AS A PLATFORM TECHNOLOGY FOR CONJUGATE VACCINES. IN AIM 1, ROBUST PROTOCOLS WILL BE ESTABLISHED FOR EXPRESSION, PURIFICATION, AND LONG-TERM STORAGE OF MQSS. IN ADDITION, HEAD TO HEAD COMPARISON WILL BE PERFORMED TO DEMONSTRATE THAT MQSS CAN ELICIT HIGHER LEVELS OF ANTIBODIES AS COMPARED TO CURRENT BENCHMARK CARRIERS. IN AIM 2, THE POWERFUL MQSS PLATFORM WILL BE APPLIED TO DELIVER SALMONELLA ASSOCIATED GLYCANS AS POTENTIAL VACCINES AGAINST MULTIPLE STRAINS OF COMMON PATHOGENIC SALMONELLA. THE VACCINE WILL BE OPTIMIZED TO ENHANCE PROTECTION FROM SALMONELLA INFECTION. WHEN SUCCESSFULLY DEVELOPED, THIS PROJECT WILL ESTABLISH MQSS AS AN ATTRACTIVE IMMUNOGENIC CARRIER FOR VACCINE DEVELOPMENT AND PROVIDE IMPORTANT PRE-CLINICAL DATA FOR ANTI-SALMONELLA VACCINES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/13/25 | ||
| Not listed | $294.6k | 6/22/22 | ||
| Not listed | $294.6k | 6/22/22 | ||
| Not listed | $300.0k | 7/9/21 | ||
| Not listed | $300.0k | 7/9/21 |